



## PRESS RELEASE

### **Biom'up, Saint Priest, Lyon, July 15th 2016.**

Today biom'up announced the enrollment of the first patient in their prospective, randomized, controlled, multicenter, pivotal, clinical investigation evaluating the safety and efficacy of **HEMOBLAST™ Bellows** in Cardiothoracic, Abdominal, and Orthopedic Lower Extremity Surgeries.

**HEMOBLAST™ Bellows** is an investigational device, not currently for sale in the US that is intended for use in surgical procedures as an adjunct to hemostasis when control of bleeding by conventional procedures is ineffective or impractical.

Since its formation in 2005, biom'up has been developing medical devices based on patent protected biopolymers. Using this experience, biom'up has created innovative and clinically proven products that cover many different surgical specialties - orthopedics, spinal, cardiac, general, and maxillo-facial and dental. biom'up is committed to the design and development of novel high-performing solutions for a better patient outcome.

#### biom'up SA

8 allée Irène Joliot Curie 69800 Saint-Priest France  
Tél : +33 4 86 57 36 10 [contact@biomup.com](mailto:contact@biomup.com)  
[www.biomup.com](http://www.biomup.com)  
Au capital de 2 191 352,00€ RCS Lyon 48101404100034  
Code NAF : 7219Z - N° de TVA intracom. : FR 04481014041

#### biom'up GmbH

Lebacher Str. 4 66113 Saarbrücken Deutschland  
Tel: +49 681 99 63 504 [kundenservice@biomup.com](mailto:kundenservice@biomup.com)

#### biom'up

50 Milk Street 16th Floor Boston MA 02109- USA  
Tel: +1 518 439 3690 [contact@biomup.com](mailto:contact@biomup.com)